IPP Bureau
Roche's Giredestrant combination meets phase III endpoints in advanced breast cancer
By IPP Bureau - September 23, 2025
Importantly, the combination of giredestrant and everolimus was well tolerated
AstraZeneca’s Tezspire recommended for approval in the EU for chronic Rhinosinusitis with nasal polyps
By IPP Bureau - September 23, 2025
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Metropolis Healthcare acquires Ambika Pathology Laboratory
By IPP Bureau - September 22, 2025
Biocon Biologics’ retinal disorder medication Yesafili gets public funding in Canada
By IPP Bureau - September 22, 2025
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
Fermenta to sell environmental solutions business to its subsidiary
By IPP Bureau - September 21, 2025
The entity will undertake the installation, operation, and maintenance of sewage treatment plants
FDA approves Merck's Keytruda injection for cancer therapy
By IPP Bureau - September 21, 2025
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
Mankind Pharma collaborates with OpenAI to drive AI-enabled transformation across value chain
By IPP Bureau - September 21, 2025
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
Datavant partners with Indegene to power clinical trial recruitment
By IPP Bureau - September 21, 2025
Collaboration matches more eligible patients, including those with rare and complex diseases, to appropriate clinical trials
Roche to acquire 89bio in $3.5B deal
By IPP Bureau - September 20, 2025
Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
Piramal Pharma Solutions boosts formulation development at Morpeth site with Korsch XM-12
By IPP Bureau - September 19, 2025
Roche secures CE mark for Accu-Chek SmartGuide CGM with mySugr app integration
By IPP Bureau - September 19, 2025
This predictive technology empowers people with diabetes to take preventive action before complications arise
Ascletis reports positive phase Ib results for oral GLP-1R agonist ASC30 at EASD 2025
By IPP Bureau - September 19, 2025
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
AllRock Bio raises $50 million to drive therapy for pulmonary hypertension into phase 2 trials
By IPP Bureau - September 19, 2025
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
CuraTeQ Biologics completes Phase 3 clinical study for Denosumab biosimilar
By IPP Bureau - September 19, 2025
Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
Sai Life Sciences opens dedicated facility for veterinary APIs in Bidar
By IPP Bureau - September 19, 2025
